Develops treatments for central nervous system disorders and depression using innovative regenerative medicine technologies.
VistaGen Therapeutics, Inc., headquartered in South San Francisco, California, operates as a dynamic clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative treatments for anxiety, depression, and other central nervous system (CNS) disorders. At the forefront of its CNS pipeline is PH94B, an advanced neuroactive nasal spray currently advancing through Phase III clinical trials. Designed for rapid-onset relief, PH94B targets acute anxiety in adults with social anxiety disorder and demonstrates potential applications across a spectrum of anxiety-related conditions including postpartum anxiety, post-traumatic stress disorder, and panic disorders.
In addition to PH94B, VistaGen Therapeutics is advancing PH10, another rapid-onset neuroactive nasal spray slated for Phase 2B clinical development as a standalone therapy for major depressive disorder (MDD). The company also focuses on AV-101, an oral N-methyl-D-aspartate receptor antagonist in development, particularly in combination with oral probenecid. AV-101 shows promise for treating conditions such as levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation, underscoring VistaGen's commitment to addressing significant unmet needs in psychiatric and neurological health.
Founded in 1998, VistaGen Therapeutics has established strategic partnerships, including a contract research and development agreement with Cato Research Ltd., a license agreement with Pherin Pharmaceuticals, Inc., and a collaborative partnership with EverInsight Therapeutics Inc. These collaborations bolster the company's capabilities in advancing innovative therapies and expanding its therapeutic portfolio to improve the lives of patients worldwide.